Skip to main content
RE-LY randomized 18,113 patients to one of its three arms. In the entire study group, dabigatran 110 mg twice per day compared with warfarin was associated with lower risks of major bleeding (2.87% vs 3.57 %), intracranial bleeding (0.23% vs 0.76%), and life-threatening bleeding (1.24% vs 1.85%).

Intermediate Dose Dabigatran for Atrial Fibrillation

July 1, 2011

RE-LY randomized 18,113 patients to one of its three arms. In the entire study group, dabigatran 110 mg twice per day compared with warfarin was associated with lower risks of major bleeding (2.87% vs 3.57 %), intracranial bleeding (0.23% vs 0.76%), and life-threatening bleeding (1.24% vs 1.85%).